SG Americas Securities LLC Makes New $391,000 Investment in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

SG Americas Securities LLC bought a new stake in shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 10,804 shares of the specialty pharmaceutical company's stock, valued at approximately $391,000.

Other institutional investors have also recently made changes to their positions in the company. Millennium Management LLC lifted its position in Supernus Pharmaceuticals by 395.1% during the second quarter. Millennium Management LLC now owns 161,332 shares of the specialty pharmaceutical company's stock worth $4,316,000 after buying an additional 128,743 shares in the last quarter. The Manufacturers Life Insurance Company increased its holdings in shares of Supernus Pharmaceuticals by 7.6% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 26,554 shares of the specialty pharmaceutical company's stock worth $710,000 after buying an additional 1,870 shares during the last quarter. Healthcare of Ontario Pension Plan Trust Fund acquired a new position in Supernus Pharmaceuticals in the second quarter valued at approximately $1,070,000. GAMMA Investing LLC increased its stake in Supernus Pharmaceuticals by 97.1% during the third quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company's stock worth $25,000 after acquiring an additional 398 shares during the last quarter. Finally, Exchange Traded Concepts LLC purchased a new stake in Supernus Pharmaceuticals in the third quarter valued at $672,000.

Analyst Upgrades and Downgrades

A number of brokerages recently issued reports on SUPN. Cowen reissued a "buy" rating on shares of Supernus Pharmaceuticals in a research report on Friday, October 18th. Cantor Fitzgerald assumed coverage on Supernus Pharmaceuticals in a research note on Monday, January 6th. They set an "overweight" rating and a $57.00 target price on the stock. Finally, Piper Sandler reiterated a "neutral" rating on shares of Supernus Pharmaceuticals in a research note on Friday, October 18th.

Insider Transactions at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of the stock in a transaction dated Tuesday, February 4th. The stock was sold at an average price of $39.70, for a total value of $376,236.90. Following the transaction, the vice president now owns 10,149 shares in the company, valued at approximately $402,915.30. This represents a 48.29 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Corporate insiders own 9.30% of the company's stock.

Supernus Pharmaceuticals Stock Performance

Shares of Supernus Pharmaceuticals stock traded down $0.45 during trading hours on Friday, reaching $38.40. 423,889 shares of the company were exchanged, compared to its average volume of 364,424. Supernus Pharmaceuticals, Inc. has a 1 year low of $25.53 and a 1 year high of $40.28. The firm has a market cap of $2.12 billion, a PE ratio of 35.89 and a beta of 0.90. The stock's fifty day moving average is $37.36 and its 200 day moving average is $34.78.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its earnings results on Monday, November 4th. The specialty pharmaceutical company reported $0.69 earnings per share for the quarter, beating the consensus estimate of $0.44 by $0.25. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The firm had revenue of $175.70 million for the quarter, compared to analysts' expectations of $157.35 million. During the same quarter last year, the company earned ($0.29) earnings per share. The firm's revenue was up 14.2% compared to the same quarter last year. Research analysts expect that Supernus Pharmaceuticals, Inc. will post 2.38 earnings per share for the current year.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.